Canada markets open in 1 hour 44 minutes

Evofem Biosciences, Inc. (EVFM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4250+0.0150 (+3.66%)
At close: 04:00PM EST
0.4200 -0.01 (-1.18%)
Pre-Market: 07:12AM EST
Sign in to post a message.
  • j
    jhon
    I have seen this happen with OCGN. Adding more shares so the greedy board can get more. They know something big is about to happen. FDA approval? In any case, this stock will get back to 1$ in order to stay listed. EASY DOUBLE!
  • a
    alan
    Shorts have managed to drop the SP further even after the type C mtg news. They have used 250k "borrowed" shares over the last 2 days to drive the price down. There are currently "0" shares left available to borrow for shorting. That doesn't mean all borrowed shares have been sold yet but there can only be a limited amount left out there. That and an RSI of 16 should indicate that the SP is close to or at a bottom.
  • i
    inbal
    HolderSharesDate Reported% OutValueVanguard Group, Inc. (The)7,009,85829 בספט׳ 20214.52%5,177,481Shaw D.E. & Co., Inc.4,502,32329 בספט׳ 20212.90%3,325,415Blackrock Inc.3,868,17929 בספט׳ 20212.49%2,857,037Baker Brothers Advisors, LLC2,697,11029 בספט׳ 20211.74%1,992,085Geode Capital Management, LLC1,342,49729 בספט׳ 20210.86%991,568Susquehanna International Group, LLP1,260,51629 בספט׳ 20210.81%931,017First Wilshire Securities Management Inc1,100,00029 בספט׳ 20210.71%812,460Fuller & Thaler Asset Management Inc.1,079,86029 בספט׳ 20210.70%797,584Millennium Management LLC650,12629 בספט׳ 20210.42%480,183Group One Trading, L.P.413,58129
  • T
    Tarcus
    30 cents per share before this month is out.
    MERRY CHRISTMAS! 🤣
  • R
    Richard
    I think that Evofem's Phexxi is a good product, but the company is in big trouble. It is unlikely that a financial institution will lend them any more money. If somebody with deep pockets does not buy the company outright, and very soon, Evofem will have a very rocky road ahead. Good luck from Weaky Zeky.
  • J
    J
    Sorry guy's, I sold my 2000 share's... it was too nerve racking.

    I wish you all the best of luck with this one though... 🌟
  • V
    VTP
    Stock is going to continue down until at a min CEO is fired. CFO should go also.
  • C
    Chi-Town
    Something is cooking...Maybe ACA Approval, EX-US Strategic Partnership, or Negotiated Discount w/ Insurers...
    SAN DIEGO, Dec. 8, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to adjourn, without conducting any business, its 2021 special meeting of stockholders (the "Special Meeting") scheduled to occur at 8:00 a.m. PST on December 8, 2021, and reconvene at 8:00 a.m. PST on December 15, 2021, to vote on the proposal described in the proxy statement filed with the Securities and Exchange Commission (the "SEC") on November 9, 2021.
  • C
    Chi-Town
    Nov 25
    Independent Chairman William Hall has left the company
    On the 17th of November, William Hall's tenure as Independent Chairman ended after 3.8 years in the role.

    As of September 2021, William still personally held only 5.00k shares (US$3.7k worth at the time).
    William is the only executive to leave the company over the last 12 months.
    The current median tenure of the management team is 3.83 years.
  • J
    Jeff
    Some people lost their life savings just to support a woman CEO.
  • a
    andrew
    don't let them dilute this co. anymore or it will be totally valueless.
  • C
    Chi-Town
    This is good news...Vote "Yes"

    As reported by that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on November 22, 2021, on November 20, 2021 the Company, certain institutional investors (the “Purchasers”) and Baker Bros. Advisors LP as their designated agent (the “Designated Agent”) entered into a first amendment (the “Amendment”) to the Securities Purchase and Security Agreement by and among the Company, the Purchasers and the Designated Agent, dated as of April 23, 2020 (the “Agreement”). The Amendment amends, effective as of the next date the Company completes one or more financings resulting in aggregate gross proceeds to the Company of at least $50 million (the “Qualified Financing Threshold”), the covenant in the Agreement currently requiring Evofem to achieve $100 million of cumulative net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate) on or prior to June 30, 2022 to require the Company to achieve $100 million in net sales on or prior to June 30, 2023.

    The Amendment also provides for an adjustment to the conversion price of the convertible senior secured promissory notes sold to the Purchasers pursuant to the Agreement such that the conversion price for these promissory notes will now be the lesser of (i) $2.44 (the current conversion price of the promissory notes) and (ii) 115% of the lowest price per share of common stock (or with respect to securities convertible in common stock, 115% of the applicable conversion price) sold in any equity financing until the Company has met the Qualified Financing Threshold. Pursuant to the Amendment, if in any financing closing on or prior to the date the Company has met the Qualified Financing Threshold, the Company issues warrants to purchase capital stock of the Company (or other similar consideration), each Purchaser will receive equivalent coverage of warrants (or other similar consideration) on the same terms as if the Purchaser had participated in the financing in an amount equal to

    https://www.streetinsider.com/dr/news.php?id=19251103&gfv=1
    Form DEFA14A Evofem Biosciences, Inc.
    www.streetinsider.com
  • a
    andrew
    what a great job . were up to 48 cents our ceo and directors should be thinking about giving themselves a raise.
  • C
    Chi-Town
    Evofem Reaches Agreement With FDA on Preliminary Submission Strategy for Chlamydia, Gonorrhea Prevention CandidateMT NEWSWIRES - 10:51 AM ET

    10:51 AM EST, 11/30/2021 (MT Newswires) -- Evofem Biosciences (EVFM) said Tuesday it has reached an agreement in a type C meeting with the US Food and Drug Administration on the preliminary submission strategy for EVO100, a candidate for the prevention of urogenital chlamydia and urogenital gonorrhea in women.

    The company said it is enrolling 1,730 women for a pivotal phase 3 trial of EVO100 across the US, and expects to report topline results from the trial in Q2 2022.

    Evofem shares were 9.4% higher in morning trading.

    MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
  • H
    Hussein
    she deleted my comment on her Instagram page as I told her distributing Phexii for free and YouTube targeted ads would have done better job than the 30 million she lost on Commercialization.
  • G
    Grandpa Jim
    Ouch!!! This is going down faster than Gabe’s wife in a room full of dudes.
  • C
    Colt
    It's quite a mystery that such a catastrophic CEO is still in her place!
  • a
    andrew
    when they increase the number of shares i'll will have to give up a cup of coffee and switch to water.
  • H
    Henry
    Can somebody tell me what happened from April 15 to July 3, 2017 when the stock dropped from $15 to $3 ?
    Bounced back and dropped to $0.45 to-day?
  • w
    wickerd
    They had some interesting insights about EVFM on (http://financialdeals.tech). Definitely made me think twice about the company.